The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
Among patients who performed percutaneous coronary intervention (PCI) in patients with
coronary artery disease (CAD), enrollment is performed in patients with moderate risk in
gastrointestinal risk assessment indicators. After obtaining the consent form, patients are
randomly assigned to the gastric acid secretion inhibitor group and the non-dose group.
Researchers and subjects proceed with the treatment group assignment, treatment-group
assignment uses a random number table and the assigned drug is disclosed. Random checks are
generated by statisticians and managed by the researchers.
In the test group, the incidence of gastrointestinal clinical events in DAPT patients is
expected to be low while taking PPI, but there is a burden of PPI costs. In the case of the
control group, the burden of PPI costs is reduced, but there is a possibility that the
incidence of clinical events may occur, although it is a small number. Subjects in the test
group will take DAPT for at least 6 months from the time of registration, and NSAIDs drugs or
steroids and NOAC or warfarin should be prohibited as combination taboo drugs when
participating in the study. Data will be collected during normal medical procedures and will
be checked through an endoscope in case of upper gastrointestinal bleeding